CINECA IRIS Institutional Research Information System

DE MERCANTI, STEFANIA FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.144
AS - Asia 3.156
EU - Europa 3.135
SA - Sud America 406
Continente sconosciuto - Info sul continente non disponibili 343
AF - Africa 139
OC - Oceania 53
Totale 13.376
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.965
SG - Singapore 1.254
IT - Italia 1.058
CN - Cina 814
VN - Vietnam 388
BR - Brasile 323
DE - Germania 321
FR - Francia 295
SE - Svezia 274
IE - Irlanda 262
GB - Regno Unito 168
FI - Finlandia 166
CA - Canada 110
UA - Ucraina 108
HK - Hong Kong 105
JP - Giappone 100
KR - Corea 95
AT - Austria 92
DK - Danimarca 85
IN - India 85
ES - Italia 54
SN - Senegal 50
BD - Bangladesh 44
NL - Olanda 44
AU - Australia 43
PL - Polonia 43
ID - Indonesia 40
IQ - Iraq 36
TR - Turchia 34
MX - Messico 33
BE - Belgio 30
RU - Federazione Russa 28
IL - Israele 26
AR - Argentina 25
IR - Iran 25
PK - Pakistan 20
GR - Grecia 19
ZA - Sudafrica 17
CZ - Repubblica Ceca 14
EC - Ecuador 14
MA - Marocco 14
UZ - Uzbekistan 13
CL - Cile 12
CO - Colombia 12
EU - Europa 11
JM - Giamaica 11
MU - Mauritius 11
RO - Romania 11
EG - Egitto 10
TW - Taiwan 10
NZ - Nuova Zelanda 9
PT - Portogallo 9
RS - Serbia 9
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
PH - Filippine 7
LT - Lituania 6
NG - Nigeria 6
SA - Arabia Saudita 6
UY - Uruguay 6
BG - Bulgaria 5
CR - Costa Rica 5
KZ - Kazakistan 5
LB - Libano 5
NO - Norvegia 5
VE - Venezuela 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
ET - Etiopia 4
HN - Honduras 4
HU - Ungheria 4
JO - Giordania 4
KG - Kirghizistan 4
MK - Macedonia 4
NP - Nepal 4
PY - Paraguay 4
AZ - Azerbaigian 3
CH - Svizzera 3
GT - Guatemala 3
KE - Kenya 3
LV - Lettonia 3
MD - Moldavia 3
MY - Malesia 3
PE - Perù 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
AL - Albania 2
BH - Bahrain 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
KH - Cambogia 2
LK - Sri Lanka 2
NI - Nicaragua 2
OM - Oman 2
PS - Palestinian Territory 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
Totale 13.020
Salva come PNG Salva come JPEG
Città #
Singapore 697
Chandler 621
San Jose 546
Ashburn 447
Beijing 374
Ann Arbor 354
Santa Clara 273
Dublin 258
Fremont 223
Fairfield 159
Torino 151
Houston 140
Milan 125
Nyköping 125
Wilmington 116
Villeurbanne 106
Turin 104
Los Angeles 103
Jacksonville 101
Dearborn 94
Munich 92
Ho Chi Minh City 90
The Dalles 88
Dallas 85
Hong Kong 85
Woodbridge 84
Medford 82
Vienna 82
Cambridge 78
Hanoi 78
Princeton 76
Columbus 73
Dong Ket 70
Lauterbourg 70
New York 69
Rome 68
Redwood City 64
Seattle 64
Tokyo 60
Guangzhou 47
Boardman 41
Boston 36
Helsinki 36
Council Bluffs 35
Hefei 35
Buffalo 33
Jakarta 32
Seoul 32
Warsaw 32
Toronto 31
Washington 29
Orem 28
Frankfurt am Main 27
Pisa 26
Turku 26
London 24
São Paulo 23
Bari 22
Brussels 21
Düsseldorf 21
Montreal 20
Naples 20
Nuremberg 20
San Francisco 19
Atlanta 18
Chicago 18
Hangzhou 18
Redondo Beach 18
Shanghai 18
Da Nang 17
Paris 17
Sydney 17
San Diego 16
Chengdu 15
Chennai 15
Haiphong 15
Baghdad 13
Memphis 13
Nanjing 13
Amsterdam 12
Brooklyn 12
Indianapolis 12
Bologna 11
Florence 11
Istanbul 11
Limoges 11
Manchester 11
Norwalk 11
Palermo 11
Rio de Janeiro 11
Falkenstein 10
Stockholm 10
Denver 9
Duncan 9
Figino 9
Mexico City 9
Ottawa 9
Salt Lake City 9
San Mateo 9
Verona 9
Totale 7.748
Salva come PNG Salva come JPEG
Nome #
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study 790
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 465
Heterozygous deletion of KLHL1/ATX8OS at the SCA8 locus is unlikely associated with cerebellar impairment in humans 456
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 443
Heterozygous deletion of KLHL1/ATXN8OS at the SCA8 locus are likely not associated with cerebellar impairment in humans 274
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 271
D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient 256
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 252
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 250
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 248
Digital therapeutics in neurology 240
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 221
The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View 213
Natalizumab in Multiple Sclerosis: Long-Term Management 207
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 193
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study 188
Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series 186
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 183
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study 183
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 179
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP 177
Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort 175
ALS patients and caregivers communication preferences and information seeking behaviour 173
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta 173
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 172
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea 171
Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question 169
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. 166
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 166
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 163
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis 163
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up 163
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study 160
Epigenetic therapy for Friedreich ataxia. 157
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 157
A real-world study of Alemtuzumab in a cohort of Italian patients 155
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients 153
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 153
Family functioning and multiple sclerosis: Study protocol of a multicentric italian project 153
Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a new biomarker of disease activity 152
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab 149
Prognostic influence of pre-morbid smoking habits, diabetes, arterial hypertension and vascular risk profile on phenotype and outcome of ALS patients: a population-based study. 145
Prophylaxis of chronic migraine with OnabotulinumtoxinA: experience and evidence in clinical practice 140
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 139
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study 134
Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome 133
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity 132
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome 131
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 129
Estrogen receptor alpha regulates key genomic regions of t-helper 17 and T-regulatory cells in Multiple Sclerosis: a new potential biomarker of disease activity. 128
Atypical presentation of superficial sclerosis successfully treated with iron chelation 127
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study 126
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 126
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 125
Extended interval dosing of natalizumab: is efficacy preserved? 125
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? 121
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta 120
The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis 120
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial 118
DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France 115
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-  115
Six year prospective immunological study of alemtuzumab treated patients: identification of markers of the clinical response 114
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia 112
Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial 110
Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b 108
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 105
Friedreich's ataxia patients and caregivers information seeking behaviour 104
Management of multiple sclerosis patients after the 24th Natalizumab course: the Ty-STOP study 103
Improving the care of Rebif® treated Multiple Sclerosis patients: the "MSdialog" experience 100
Ultrasound-guided botulinum toxin-A for sialorrhea: a 2-year prospective study 99
Role of Th22 expansion in multiple sclerosis disease activity 92
PRO-INFLAMMATORY CYTOKINE AND CHEMOKINE MRNA BLOOD LEVEL IN MULTIPLE SCLEROSIS IS RELATED TO TREATMENT RESPONSE AND INTERFERON-BETA DOSE 88
Signs and symptoms of COVID‐19 in patients with multiple sclerosis 87
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study 83
Spinal Cord Compression due to extramedullary hematopoiesis in a young patient affected by beta thalassemia 79
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey 79
A real‐world study of alemtuzumab in a cohort of Italian patients 74
Natalizumab discontinuation after the 24th course: which is the way? The TY-STOP study 68
EPIGENETIC THERAPY FOR FRIEDREICH’S ATAXIA: A PHASE 1, FIRST IN MAN, ASCENDING DOSE CROSSOVER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RG2833 (A HISTONE DEACETYLASE INHIBITOR) IN ADULTS WITH FRIEDREICH’S ATAXIA 56
Source of medical information and behavioral seeking patterns in patients affected with Friedreich’s ataxia and their caregivers: a survey study 48
Totale 13.376
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.079
article - articoli 0
book - libri 0
conference - conferenze 19.690
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.769
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.102 0 42 36 74 48 89 89 65 73 120 261 205
2022/20231.643 137 164 51 196 146 377 103 107 167 63 82 50
2023/2024732 99 106 56 48 51 121 25 39 0 49 50 88
2024/20251.930 42 74 88 171 404 141 51 102 274 121 158 304
2025/20264.176 402 143 262 411 419 193 571 141 361 344 167 762
2026/2027215 182 33 0 0 0 0 0 0 0 0 0 0
Totale 13.376